key: cord-1010180-3yp4fecz
authors: Sanchis-Gomar, Fabian; Lavie, Carl J.; Mehra, Mandeep R.; Henry, Brandon Michael; Lippi, Giuseppe
title: Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide
date: 2020-05-19
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.05.006
sha: b2b5591bfad3195393ee8c5771c4f21f7a27947f
doc_id: 1010180
cord_uid: 3yp4fecz

Abstract Obesity has reached epidemic proportions in the United States and in much of the Westernized World, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk of death with Coronavirus 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates human cells through direct binding with angiotensin-converting enzyme (ACE) 2 receptors on the cell surface. ACE2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19, including respiratory failure, need for mechanical ventilation, and higher mortality. Clinicians need to be more aggressive when treating obese, especially severely obese, patients with COVID-19.

Obesity is at epidemic levels in the United States (US) and in most of the Westernized World. 1 Nearly three-fourths of adults over the age of 20 years in the US meet criteria for being overweight or obese, and 42% are obese [body mass index (BMI) ≥30 kg/m 2 ]. Over 9% of the US adult population meet criteria for morbid, or severe (Class III) obesity, with a BMI ≥40 kg/m 2 . Other westernized countries have also noted increasing prevalence of obesity. 2 Obesity is known to influence the vast majority of major cardiovascular (CV) disease (CVD) risk factors, including dysglycemia, metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), elevated blood pressure and hypertension (HTN), with adverse effects on CV structure and function. 3, 4 Additional morbidity includes chronic lung disease, asthma, and systemic inflammation. 4, 5 Not surprisingly, almost all forms of CVD are increased in the setting of increased adiposity, 6 especially heart failure (HF), especially HF with preserved ejection fraction (HFpEF), as well as HTN, coronary heart disease (CHD), atrial fibrillation (AF), and peripheral arterial disease. 4, 5, 7, 8 Many reports identified obesity and severe obesity as risk factors for hospitalization, mechanical ventilation and mortality from H 1 N 1 Influenza. 9 Obesity increases the duration of virus shedding of influenza A virus. 10 Based on currently available information and clinical expertise, the Centers for Disease Control and Prevention (CDC) has identified severe obesity (i.e., BMI ≥40 kg/m 2 ), as a common clinical risk factor for worse prognosis and higher mortality in coronavirus disease 2019 (COVID-19) patients. 11 Furthermore, any degree of obesity (BMI ≥30 kg/m 2 ), has been associated with poor prognosis in patients with COVID-19. 12 © 2020 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2020;95(x):xx-xx.

We and others proposed the "obesity paradox", which suggests that overweight and those obese with established CVD appear to have a better short-and medium-term prognosis compared with their lean counterparts. We believe that this obesity paradox is "heavily" influenced by physical activity (PA) and fitness, since generally those with high PA and fitness have a good prognosis regardless of weight, whereas the leaner patients with CVD and low PA/fitness have particularly poor prognosis. 4, 5, 7, 13, 14 Nevertheless, many obesity and CVD prognosis papers do not include data on PA/fitness. We have demonstrated this obesity paradox in patients with lung diseases, including chronic obstructive pulmonary disease (COPD) and pulmonary embolism, 15, 16 as well as in patients with advanced renal disease. 17 However, evidence suggests that obesity may be detrimental in COVID-19 patients, 18 with potential for more development of disease, worse outcomes, including respiratory and multiple organ failure, and higher mortality (Figure 1) . 1,12 19,20 Interestingly, ageing and obesity share numerous causative mechanisms largely linked to a dysfunctional adipose tissue, such as metabolic dysfunction, multi-organ damage, endocrine disruption, impaired immune function, and chronic inflammation. 21

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates human cells through direct binding with angiotensin-converting enzyme 2 (ACE2) receptors on the cell surface. The obese demonstrate insulin-resistance and an overactivity of the reninangiotensin-aldosterone system (RAAS), which is implicated with worse outcomes in COVID-19 (Table 1) . 22 ACE2 expression in adipose tissue is higher than that in the lung, a major target organ affected by COVID-19, 23 suggesting that adipose tissue may be more vulnerable to COVID-19 infection. The obese population have more adipose tissue and consequently higher levels of ACE2 (Figure 2, right panel) . 23 The affinity between ACE2 and SARS-CoV-2 is several-fold higher than the affinity between ACE2 and the former SARS-CoV. 24 The presence of ACE2 may enable the entry of SARS-CoV-2 into adipocytes, which makes adipose tissue an important viral reservoir. 20 Accordingly, adipose tissue might also be infected by SARS-CoV-2 and allow spread to other organs. 25 Moreover, obesity, along with low PA/fitness, is the leading cause of T2DM, and T2DM is also causally linked with elevated ACE2 expression. 26 Cells expressing ACE2 are also connected to progression of idiopathic pulmonary fibrosis (IPF). 20

Obesity may induce alterations in the RAAS that promote further derangement in COVID-19. Adipocytes may substantially contribute to the production of circulating angiotensinogen, which after metabolism by renin and ACE, produces angiotensin II (Ang II). 27 As such, obesity may lead to an overactive RAAS (Figure 2, left panel) . In a small study by Liu et al., 28 patients with COVID-19 were shown to have elevated levels of Ang II that correlated with severity of lung injury measured by PaO 2 /FiO 2 ratio. High levels of Ang II in the lung can induce pulmonary vasoconstriction leading to ventilation/perfusion mismatch and hypoxemia, as well as inflammation and oxidative damage, promoting acute lung injury. 29, 30 In obese individuals with T2DM, Ang II levels were shown to positively correlate with body weight. 31 Thus, the elevated baseline Ang II in the obese may exacerbate COVID-19 induced Ang II increase, leading to more severe lung injury. Interestingly, Ang II levels decreased in response to dietary weight loss. 31 As such, dietary modification and PA may be beneficial at reducing this potential mechanism of enhanced COVID-19 disease in obesity.

CVD is significantly increased with obesity, 32 which represents an important risk factor for CHD and more so for HF. Obesity is also linked to other numerous risk factors for CHD, i.e., T2DM, high low-density lipoprotein cholesterol, triglycerides, HTN, and MetS. 33 Importantly, T2DM and HTN themselves also represent a frequent comorbidity in COVID-19 patients. The risk for CHD is higher in people with "central" or "visceral" obesity (concentrated in the abdomen). Likewise, obesity is one of the leading risk factors for AF; in many cases, AF is present in obese with HF, especially HFpEF. 32 Accordingly, the pathways among obesity, HF and AF are all closely related. 32 In effect, AF is a common comorbidity present in severe forms of COVID-19, which may lead to a worse prognosis or even higher mortality. In a report published by the Italian National Institute of Health, approximately onequarter of patients who died for COVID-19 had AF, which was hence the fourth most common condition in these patients. 34 Moreover, data provided by the New York State Department of Health also reported that AF is among the top ten COVID-19 comorbidities, specifically occupying the seventh position. 35 In this regard, Mehra et al. 36 have recently reported that cardiac arrhythmia is independently associated with an increased risk of inhospital mortality in 8,910 COVID-19 patients.

Additionally, obesity is associated with impaired pulmonary function, with decreased expiratory reserve volume, functional capacity and respiratory system compliance. 9 Increased abdominal obesity compromises pulmonary function in supine patients by decreased diaphragmatic excursion, while the base of the lungs ventilation is also impaired, resulting in reduced oxygen-saturated blood levels. 9 Furthermore, chronic, low-grade inflammation and increased circulating pro-inflammatory cytokines associated with obesity, such as leptin, tumor necrosis factor (TNF)-α, and interleukin-(IL) 6, may impair immune response, affect the lung parenchyma and bronchi, thus contributing to the increased morbidity associated with obesity in COVID-19 infection. There is evidence of endothelial dysfunction in obesity, 5 as well as renal disease, 37 and this may lead to more potential for endothelial cell infection in obesity, as discussed below.

Obesity-related endothelial dysfunction is caused by several mechanisms, such as low-grade inflammation, produced by either by perivascular adipose tissue or the vasculature itself. 38 Endothelial dysfunction results from an imbalance in production of vasodilatory and vasoconstricting agents. 39 These alterations prompt the vascular endothelium towards prothrombotic and proatherogenic states, reflected by platelet hyper-activation, enhanced leukocyte adhesiveness, vasoconstriction, pro-oxidation, mitogenesis, vascular inflammation, impaired hemostasis, atherosclerosis, and thrombosis, with subsequent increased CVD. 39 These factors all provoke the development of, and the further progression to, vascular endothelial dysfunction, with subsequent damage to some vital organs. Varga treatment, particularly for more vulnerable patients with worse prognosis (i.e., patients with pre-existing endothelial dysfunction associated with male sex, chronic respiratory diseases, HTN, T2DM, obesity, and established CVD). 40 Chronic kidney disease (CKD) are also among the top ten COVID-19 comorbidities. 35, 41 Obesity provokes structural and functional changes at the nephron level, including podocyte dysfunction with decreased podocyte density and number, podocyte hypertrophy, glomerular capillary hypertension and glomerular hypertrophy, glomerulomegaly, and a secondary adaptive form of focal and segmental glomerulosclerosis in the long term. 37 Besides, central adiposity decreases estimated glomerular filtration rate and effective renal plasma flow, as well as increases filtration fraction, leading to sub-nephrotic proteinuria. 37 Overall, obesity increases the odds of developing two of the major risk factors with direct impact on the progress to CKD, i.e., T2DM and HTN, and end-stage renal disease (ESRD). 42 Again, therapy with ACEi and angiotensin receptor blockers (ARBs) has been shown to protect the kidneys and delay progression of CKD in T2DM patients, being the preferred drugs in CKD patients. 43 For that reason, and in agreement with Varga et al., 40 ACEi/ARBs may be recommended as part of the treatment armamentarium for COVID-19. 44 Whether ACEi is more recommendable than ARBs or vice versa, Mehra et al. 36 showed that ACEi were independently associated with a reduction in mortality in a subgroup with hypertension whereas ARBs were associated with no increased risk of in-hospital death . In an even larger study of 96,032 hospitalized COVID-19 patients from across 6 continents, Mehra and colleagues were able to re-confirm the association of use of ACEi therapy with a reduced mortality, whereas ARBs had a neutral effect. 45 Finally, immune dysfunction is also linked to obesity, with increased susceptibility to infection or bacteremia. 46 

COVID-19 patients are at risk for venous thromboembolism (VTE), even when anticoagulated, and/or are at risk for disseminated intravascular coagulation (DIC). 49 Severity of COVID-19 patients is intimately connected with a hypercoagulable status and thrombosis, 50,51 the so called "COVID-19-associated coagulopathy" or "sepsis-induced coagulopathy." Fulminant activation of coagulation and consumption of clotting factors reflected by moderate to severe thrombocytopenia, prolongation of the prothrombin time and activated partial thromboplastin time, elevation of D-dimer, and decreased values of fibrinogen has been observed in severe COVID-19 infection. 52 Abnormal coagulation parameters are associated with poor prognosis in all patients with severe coronavirus pneumonia. 53 Many of COVID-19 patients who die during hospitalization also show criteria of DIC. 53 Notably, D-dimer has been associated with the severity of COVID-2019, and thus represents a useful index for identifying patients at higher risk of developing VTE. 54 An increased incidence of VTE among COVID-19 patients with severe pneumonia has also been reported, which may be related to poor prognosis. 55 Importantly, obesity and overweight have been consistently associated with an increased risk of developing VTE. [56] [57] [58] Hypercoagulability has been found in overweight patients without MetS and increases with the severity of obesity. 59 patients were also more likely to be obese (39.8% vs. 14.5%). Moreover, BMI >40 kg/m 2 was found to be the strongest risk factor for hospitalization (OR 6.2, 95% CI, 4.2-9.3).

Lighter and coworkers 64 hospital system in New York City between March 4 and April 4, 2020. Of the 3,615 symptomatic patients who tested positive, 775 (21%) had BMI between 30 and 34 kg/m 2 , and 595 (16%) had BMI >35 kg/m 2 . Patients aged <60 years with BMI between 30 and 34 kg/m 2 were 2-fold (95% 1.6-2.6, p<0.0001) and 1.8-fold (95% CI 1.2-2.7, p=0.006) more likely to be admitted to acute and critical care, respectively, compared to individuals with BMI <30 kg/m 2 . Moreover, COVID-19 patients with BMI >35 kg/m 2 and aged <60 years were 2.2-fold (95% CI 1.7-2.9, p<.0001) and 3.6-fold (95% CI 2.5-5.3, p=<.0001) more likely to be admitted to acute and critical care compared to patients in the same age category and with a BMI <30 kg/m 2 .

Additionally, Goyal and collaborators 65 

There is a large evidence supporting the role of PA or exercise training (ET) in decreasing inflammation in overweight or obese individuals. 14 PA/ET prevents CVD and improves the prognosis of patients with CVD, particularly CHD and HF. In obese patients with CHD and/or HF, survival rates are excellent regardless of adiposity when fitness is preserved. Thus, improving fitness via PA/ET is needed for primary and secondary prevention of CVD and all-cause mortality in obese populations. 14 Maintain body weight and remaining fit represents a crucial goal for possible future pandemics.

Obesity represents a risk factor for higher severity and worse prognosis in COVID-19 patients. Likewise, obesity-induced adipose tissue inflammation and its effects on the immune system play a crucial role in the pathogenesis of COVID-19 infection. Moreover, it also results in metabolic dysfunction, which may lead to dyslipidemia, insulin resistance, CVD, MetS/ T2DM, and HTN. Older age also represents a risk factor for poor prognosis in COVID-19 patients. Clearly, prevention of obesity in the first place, and especially, its progression to more severe forms is desperately needed throughout the healthcare system and society. These efforts are also needed to help improve prognosis in the next pandemic, as well as for primary and secondary prevention of CVD and DM. In the ongoing COVID-19 pandemic, clinicians should recognize that the obese, and more so the more severely obese, are at higher risk of clinical deterioration with COVID-19. As such, these patients need to be carefully monitored and treated more aggressively to reduce morbidity and mortality.

1. Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the Patient with Obesity -The Editors Speak Out. Obesity (Silver Spring). 2020. Abbreviations: AF, atrial fibrillation, EGFR, estimated glomerular filtration rate; ERPF, effective renal plasma flow; ERS, expiratory reserve volume; ESRD, end-stage renal disease; FC, functional capacity; FF, filtration fraction; HDL, high-density lipoprotein, HFpEF, heart failure with preserved ejection fraction; IL-6, interleukin-6; LDL, low-density lipoprotein; RSC, respiratory system compliance; TNF-α, tumor necrosis factor alpha. Figure 2 . Scheme of the effects of SARS-CoV-2 infection in obese individuals. Increased production of angiotensinogen by adipose tissue leads to elevated Ang II in obesity. SARS-CoV-2 attenuates metabolism of Ang II by binding to ACE2 promoting a system imbalance. High Ang II leads to pulmonary vasoconstriction and inflammation that contributes to acute lung injury (left side of the figure). ACE2 expression in adipose tissue is higher than that in the lung, a major target organ affected by COVID-19. Increased ACE2 expression in adipocytes may make them more vulnerable to SARS-CoV-2 infection and a potential viral reservoir leading to a prolonged viral clearance (right side of the figure). Abbreviations: ACE, angiotensin-converting enzyme; Ang 1-7, angiotensin-(1-7); Ang 1-9, angiotensin-(1-9); AT1R, angiotensin II type I receptor; MasR, G-protein coupled Mas receptor. Table 1 . Obesity-associated comorbidities potentially implicated in worsening prognosis in COVID-19 patients. Adapted from Prog Cardiovasc Dis 37 with permission. T2DM, type 2 diabetes mellitus; SNS, sympathetic nervous; RAAS, renin-angiotensin-aldosterone; HTN, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; PAH, pulmonary arterial hypertension.

-Insulin resistance, pre-diabetes and T2DM.

-Dyslipidemia including hypertriglyceridemia.

Autonomic nervous system -Chronic and excessive activation of the SNS and the RAAS systems.

-Systemic arterial HTN, CVD and CKD.

Immune system -Chronic inflammatory reaction.

-Atherosclerotic and non-atherosclerotic CVD, and cerebrovascular disease.

-HTN, including treatment-resistant HTN.

Pulmonary and sleep apnea -Sleep-disordered breathing, obesity hypoventilation syndrome and obstructive sleep apnea.

-Secondary chronic hypoxia, PAH, and cor pulmonale -Systemic arterial HTN which may be treatment resistant.

-Hypercoagulability and a tendency to thromboembolic disease Cancer -Increased risk of cancer: colon, gastric, esophageal, hepatic, biliary duct, pancreatic and renal cell.

COVID-19 and obesity: Links and risks

Healthy Weight and Obesity Prevention: JACC Health Promotion Series

An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases

Twenty-First Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient

Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise

The Impact of Obesity in Heart Failure

Obesity and its Implications for COVID-19 Mortality

Obesity Increases Mortality and Modulates the Lung Metabolome during Pandemic H1N1 Influenza Virus Infection in Mice

Groups at Higher Risk for Severe Illness

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease

Sustained Physical Activity, Not Weight Loss, Associated With Improved Survival in Coronary Heart Disease

Effects of Physical Activity, Exercise, and Fitness on Obesity-Related Morbidity and Mortality

Survival Benefit of Obese Patients With Pulmonary Embolism

Obesity paradox: does fat alter outcomes in chronic obstructive pulmonary disease?

JAMA patient page. Obesity and the heart

Obesity, Central Adiposity, and Fitness: Understanding the Obesity Paradox in the Context of Other Cardiometabolic Parameters

Characteristics of COVID-19 patients dying in Italy Report based on available data on April 6th

Cardiovascular disease, drug therapy, and mortality in Covid-19

Obesity and Kidney Disease

Endothelial Dysfunction in Obesity: Role of Inflammation

Endothelial Dysfunction in Obesity-Induced Inflammation: Molecular Mechanisms and Clinical Implications

Endothelial cell infection and endotheliitis in COVID-19

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection

World Kidney Day Steering C. Obesity and Kidney Disease: Hidden Consequences of the Epidemic

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Angiotensin-Converting Enzyme 2 and Anti-Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19)

Hydroxychloroquine or Chloroquine with or without a Macrolide and Outcome in COVID-19: A Multinational Registry Analysis

Leptin in immunology

Physical activity for immunity protection: Inoculating populations with healthy living medicine in preparation for the next pandemic

T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Obesity and thrombosis

Thrombosis and obesity: cellular bases

Association between obesity and a prothrombotic state: the Framingham Offspring Study

Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events

Hemostatic abnormalities associated with obesity and the metabolic syndrome

Obesity, haemostasis and the fibrinolytic system

Inflammation, obesity, and thrombosis

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Clinical Characteristics of Covid-19 in New York City